BEAM: Durable gene editing advances in AATD, PKU, and sickle cell drive clinical and commercial momentum
Gene editing programs are advancing with strong clinical data in AATD, PKU, and sickle cell, leveraging base editing and integrated manufacturing. BEAM-302 shows durable efficacy and safety, while BEAM-304 and risto-cel are positioned for rapid development and commercial impact.Based on Beam Therap…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.